Drugs / Propofol
Propofol
also known as
Diprivan · 2, 6-diisopropyl phenol · Fresofol · Pro · ICI35,868 · Propofol (Diprivan) · Propofol Fresenius · Propofol Kabi · +21 more
Small molecule targets HOXA11-AS, NOS2, TRPA1 via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | DIPRIVAN | — | 1991-12-31 – 2001-02-23 | fda.gov ↗ |
| Approved | US (FDA) | DIPRIVAN | — | 1989-10-02 | fda.gov ↗ |
Trials 480 · started per year
today
US approved 1989
1
2
5
7
3
11
6
15
13
14
17
17
22
36
30
32
31
26
17
25
24
26
24
27
25
23
1989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials | ||||||
| Phase 0 | NCT07294092 | Apr 2026 → Aug 2028 expected | — | Keith M Vogt | Recruiting | No outcome recorded |
| Phase 0 | NCT06626711 | Oct 2024 → Nov 2025 overdue | cancer | Saint Petersburg State University, Russia | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06870357 | Jan → Jun 2024 | — | Second Hospital of Shanxi Medical University | Completed | No outcome recorded |
| Phase 0 | NCT05272202 | Jan 2023 → Dec 2026 expected | — | Brugmann University Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05246371 | Jun → Nov 2021 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 0 | NCT04998253 | Oct → Nov 2020 | COVID-19, acute respiratory distress syndrome | Unidad Temporal COVID-19 en Centro Citibanamex | Completed | No outcome recorded |
| Phase 0 | NCT03498235 | Mar 2018 → Jun 2020 | — | Obstetrics & Gynecology Hospital of Fudan University | Unknown | No outcome recorded |
| Phase 0 | NCT02786329 | Jun 2016 → Aug 2022 | colorectal cancer | Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor | Unknown | No outcome recorded |
| Phase 123 trials | ||||||
| Phase 1 | NCT07828470 | Oct → Nov 2026 expected | — | Hunan Kelun Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07198711 | May 2025 → May 2027 expected | — | Stanford University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT05742789 | Nov 2021 → Jan 2023 | aortic valve insufficiency, mitral valve insufficiency | Astana Medical University | Completed | No outcome recorded |
| Phase 1 | NCT05695287 | Jan 2021 → Nov 2022 | aortic valve insufficiency, coronary artery disorder, mitral valve insufficiency | Astana Medical University | Completed | No outcome recorded |
| Phase 1 | NCT04680910 | Jan 2021 → Jul 2024 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT04062123 | Jul 2020 → Apr 2024 | — | Keith M Vogt | Completed | No outcome recorded |
| Phase 1 | NCT04162535 | Nov 2018 → Dec 2023 | colorectal cancer | Iuliu Hatieganu University of Medicine and Pharmacy | Unknown | No outcome recorded |
| Phase 1 | NCT03362775 | Nov 2018 → Oct 2023 | — | Central Hospital, Nancy, France | Unknown | No outcome recorded |
| Phase 1 | NCT03311581 | Sep 2017 → Jun 2021 | end stage renal failure | Kaohsiung Medical University Chung-Ho Memorial Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02935647 | Oct 2016 → Sep 2018 | major depressive disorder | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT02040909 | Jul 2014 → Jan 2018 | — | Erasmus Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT02043977 | Jun 2013 → May 2015 | insomnia, sleep-wake disorder | Life Extension Foundation Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01342328 | May → Nov 2012 | sleep disorder | University of California, San Francisco | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01550770 | Feb → Jul 2012 | — | Ethicon Endo-Surgery | Completed | No outcome recorded |
| Phase 1 | NCT01593397 | Nov 2011 → Sep 2017 | obesity disorder | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT01447875 | May 2011 → Dec 2013 | infectious disease with sepsis | Southeast University, China | Completed | No outcome recorded |
| Phase 1 | NCT01591148 | Jan 2011 → Jul 2017 | morbid obesity | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT01191021 | Aug → Oct 2010 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT02229201 | May 2010 → Dec 2013 | — | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 1 | NCT01736020 | Sep 2009 → Apr 2017 | — | Southern California Institute for Research and Education | Unknown | No outcome recorded |
| Phase 1 | NCT00908726 | May 2009 → May 2010 | — | Asan Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00826553 | Jan 2009 → Dec 2013 | delirium, respiratory failure | Vanderbilt University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00142493 | Sep 2004 → Aug 2008 | amnestic disorder | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07672301 | Mar 2026 → Jun 2027 expected | — | University of Chicago | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07086911 | Aug 2025 → Aug 2026 overdue | — | Jinqiao Qian | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06545890 | Aug → Nov 2024 overdue | delirium | Cairo University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03928366 | Jun 2017 → Jan 2019 | codeine toxicity | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1/2 | NCT02050893 | May 2012 → Apr 2013 | infectious disease with sepsis | Southeast University, China | Completed | No outcome recorded |
| Phase 216 trials · 1 missed | ||||||
| Phase 2 | NCT06577636 | Jul 2025 → Dec 2028 expected | post-traumatic stress disorder | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT06867549 | Mar 2025 → Feb 2028 expected | depressive disorder | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06403852 | May 2024 → Oct 2025 | — | University of Michigan | Completed | No outcome recorded |
| Phase 2 | NCT05759481 | Feb 2024 → Mar 2025 | — | Milton S. Hershey Medical Center | Completed | Missed primary |
| Phase 2 | NCT05303987 | Oct 2022 → Jan 2027 expected | obstructive sleep apnea syndrome | Erin Kirkham | Recruiting | No outcome recorded |
| Phase 2 | NCT05495945 | Aug 2022 → Oct 2023 | — | University of Michigan | Completed | No outcome recorded |
| Phase 2 | NCT04790734 | May 2021 → Apr 2022 | — | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Completed | No outcome recorded |
| Phase 2 | NCT03807297 | Jan → Nov 2019 | — | Rajiv Gandhi Cancer Institute & Research Center, India | Completed | No outcome recorded |
| Phase 2 | NCT04072328 | Oct 2018 → Aug 2020 | — | DongGuk University | Completed | No outcome recorded |
| Phase 2 | NCT03498391 | Jul 2018 → May 2023 | — | University of Pennsylvania | Suspended | No outcome recorded |
| Phase 2 | NCT02839668 | Aug 2016 → Sep 2019 | breast cancer | Iuliu Hatieganu University of Medicine and Pharmacy | Completed | No outcome recorded |
| Phase 2 | NCT02036736 | Apr 2013 → Dec 2014 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT01621373 | Aug 2012 → Jul 2014 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 2 | NCT00228267 | Sep 2004 → Nov 2007 | headache disorder | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT00478907 | Mar 2004 → Mar 2006 | strabismus | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00209521 | Jun 2002 → Jul 2003 | coronary artery disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 2/311 trials · 3 missed | ||||||
| Phase 2/3 | NCT06418893 | Aug 2023 → Oct 2024 | — | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| Phase 2/3 | NCT03684447 | Apr 2019 → Dec 2022 | — | University of Utah | Completed | No outcome recorded |
| Phase 2/3 | NCT03923361 | Apr 2019 → Mar 2024 | — | University of Utah | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02700893 | Mar → Aug 2016 | cerebrovascular disorder | Centre Hospitalier Intercommunal Creteil | Completed | Missed primary |
| Phase 2/3 | NCT02393664 | Mar 2015 → Oct 2016 | lung neoplasm | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02105415 | Apr 2014 → Nov 2017 | — | Mayo Clinic | Completed | Missed primary |
| Phase 2/3 | NCT01604785 | Nov 2012 → Aug 2016 | migraine disorder | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2/3 | NCT01490580 | May 2012 → Aug 2016 | — | Centre Hospitalier Intercommunal Creteil | Completed | Missed primary |
| Phase 2/3 | NCT01958138 | Apr → Dec 2012 | — | Aga Khan University | Completed | No outcome recorded |
| Phase 2/3 | NCT01326078 | Jun → Jul 2011 | leukemia | Cristália Produtos Químicos Farmacêuticos Ltda. | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00734383 | Apr 2005 → May 2012 | myocardial infarction | University of British Columbia | Completed | No outcome recorded |
| Phase 330 trials · 2 met primary · 1 missed | ||||||
| Phase 3 | NCT07627906 | Jul → Dec 2026 expected | delirium | Cairo University | Recruiting | No outcome recorded |
| Phase 3 | NCT07530146 | May → Oct 2026 expected | infectious disease with sepsis, pneumonia | Helwan University | Recruiting | No outcome recorded |
| Phase 3 | NCT07303985 | Dec 2025 → Feb 2026 | — | Jun Zhang | Completed | No outcome recorded |
| Phase 3 | NCT06733129 | Apr 2025 → Apr 2027 expected | — | Nantes University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07019805 | Sep 2024 → Mar 2025 | acute hypotension | Indonesia University | Completed | No outcome recorded |
| Phase 3 | NCT05615025 | Jan → Jun 2023 | neuromuscular junction disease | Brugmann University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05358535 | Sep 2022 → Jan 2027 expected | — | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT05263674 | Feb 2022 → Dec 2027 expected | epilepsy | University of Southern Denmark | Recruiting | No outcome recorded |
| Phase 3 | NCT03841812 | Jan → Jun 2020 | — | China International Neuroscience Institution | Completed | No outcome recorded |
| Phase 3 | NCT05696509 | Jan 2020 → Oct 2022 | aortic valve insufficiency, mitral valve insufficiency | Astana Medical University | Completed | No outcome recorded |
| Phase 3 | NCT04016246 | Oct 2019 → Mar 2024 | respiratory distress syndrome in premature infants | University Hospital, Grenoble | Completed | Met primary |
| Phase 3 | NCT02734511 | May 2017 → Sep 2019 | — | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Phase 3 | NCT03022240 | Jan 2017 → Sep 2019 | — | University of Calgary | Completed | No outcome recorded |
| Phase 3 | NCT04486690 | Jul 2016 → Jun 2017 | — | ghada fouad | Completed | No outcome recorded |
| Phase 3 | NCT02492282 | Jun → Dec 2015 | — | Universidad de Antioquia | Completed | No outcome recorded |
| Phase 3 | NCT01856998 | May 2013 → Feb 2014 | — | Fresenius Kabi | Completed | No outcome recorded |
| Phase 3 | NCT01387139 | Jan 2011 → Jan 2014 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 3 | NCT02046720 | Jun 2010 → Nov 2013 | — | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 3 | NCT00741949 | Sep 2008 → Jun 2011 | acute respiratory failure | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 3 | NCT00690495 | May → Sep 2008 | — | B. Braun Melsungen AG | Completed | No outcome recorded |
| Phase 3 | NCT01242241 | Apr 2008 → Dec 2011 | obesity disorder | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00741351 | Dec 2007 → Mar 2009 | — | Azienda Ospedaliera San Gerardo di Monza | Completed | No outcome recorded |
| Phase 3 | NCT00506246 | Jun → Oct 2007 | — | B. Braun Melsungen AG | Completed | No outcome recorded |
| Phase 3 | NCT00559468 | Dec 2006 → Mar 2007 | — | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00405522 | Nov 2006 → Jun 2007 | — | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 3 | NCT00389883 | Nov 2006 → Jan 2010 | supratentorial cancer | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 3 | NCT00336882 | Jun 2006 → Oct 2009 | traumatic brain injury | Rennes University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT00219856 | Aug 2004 → Mar 2006 | — | Rennes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00192959 | Mar → Dec 2004 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 3 | NCT00287560 | Aug 2003 → Feb 2005 | — | B. Braun Melsungen AG | Completed | No outcome recorded |
| Phase 4169 trials · 12 met primary · 5 missed | ||||||
| Phase 4 | NCT07653867 | Nov 2026 → Jun 2028 expected | — | Karolinska Institutet | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07637279 | Nov 2026 → Jun 2028 expected | polyp of large intestine | Karolinska Institutet | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07807579 | Oct 2026 → Nov 2027 expected | traumatic brain injury | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07816068 | Oct 2026 → Oct 2027 expected | delirium, thoracic aortic aneurysm | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07806006 | Sep 2026 → Sep 2027 expected | abdominal aortic aneurysm | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07836205 | Sep 2026 → Sep 2028 expected | — | Beijing Chao Yang Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07644663 | Jun → Aug 2026 overdue | — | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07601698 | May → Nov 2026 expected | — | Sohag University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07334132 | Apr 2026 → Dec 2029 expected | osteoarthritis | Region Örebro County | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07556523 | Mar 2026 → Apr 2028 expected | aortic valve stenosis | David Lyubashevsky | Recruiting | No outcome recorded |
| Show all 169 trials opens the full record — a long page | ||||||
| Phase not applicable218 trials · 15 met primary · 8 missed | ||||||
| — | NCT07805876 | Sep 2026 → Sep 2028 expected | brain neoplasm | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07806162 | Sep → Oct 2026 expected | — | Sohag University | Not yet recruiting | No outcome recorded |
| — | NCT07788157 | Jul → Sep 2026 overdue | — | Tongji Hospital | Recruiting | No outcome recorded |
| — | NCT07678216 | Jul 2026 → Jun 2028 expected | traumatic brain injury | Aswan University | Not yet recruiting | No outcome recorded |
| — | NCT07460050 | Mar → Aug 2026 overdue | — | Hayatabad Medical Complex | Not yet recruiting | No outcome recorded |
| — | NCT07534956 | Jan 2026 → Oct 2027 expected | — | Marmara University Pendik Training and Research Hospital | Recruiting | No outcome recorded |
| — | NCT07325669 | Jan 2026 → Jan 2027 expected | — | dilara gocmen | Not yet recruiting | No outcome recorded |
| — | NCT07304206 | Dec 2025 → Feb 2026 | — | Inonu University | Completed | No outcome recorded |
| — | NCT07271472 | Dec 2025 → May 2026 | — | Ataturk University | Completed | No outcome recorded |
| — | NCT07204106 | Oct → Nov 2025 | — | Shiyou Wei | Completed | Met primary |
| Show all 218 trials opens the full record — a long page | ||||||
| Comparator or background therapy957 trials | ||||||
| Phase 0 | NCT07247968 Background | Nov 2025 → Nov 2026 expected | depressive disorder | Min Su | Recruiting | No outcome recorded |
| Phase 0 | NCT06756178 Comparator | Jan 2025 → Nov 2026 expected | delirium | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06717945 Comparator | Jan → May 2025 overdue | — | Chinese Academy of Medical Sciences, Fuwai Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06561672 Background | Sep 2024 → Mar 2025 overdue | — | Zagazig University | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06368219 Comparator | Apr → Sep 2024 | — | Alexandria University | Unknown | No outcome recorded |
| Show all 957 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-06-10 | Sedana Medical | Results Both of Sedana Medical´s pivotal US studies meet first key secondary endpoint sedanamedical.com ↗
In both studies, the dose reduction was significantly greater in the isoflurane group than in the propofol group. |
| 2023-07-26 | Impax Laboratories, LLC | Regulatory Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics amneal.com ↗
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has submitted Abbreviated New Drug Applications (“ANDA”) to the U.S. Food and Drug Administration (FDA) for three key complex generic products, including: |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-10 | Sedana Medical | Both of Sedana Medical´s pivotal US studies meet first key secondary endpoint sedanamedical.com ↗ |
| 2023-07-26 | Impax Laboratories, LLC | Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics amneal.com ↗ |
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 1,439 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Propofol | “Participants will be induced using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, followed by 0.6 mg/kg IV rocuronium, and IV propofol with dosage at the...” NCT06029049 ↗1435“Eighty females (20-65 years old) undergoing thyroid surgery were prospectively recruited and randomized to either the TIVA (effect-site target controlled infusion using...” PMID 25500679 ↗ Dec 2014 “This project is based on a previous randomized, double blind prospective trial (conducted by one of these authors and not yet published) comparing two groups of patients who...” NCT04005599 ↗ “1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine...” NCT03176758 ↗ “Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，propofol 0.1-0.25 ml/kg for induction, propofol 0.4\~ 1.2...” NCT07019246 ↗ “The investigators will not mandate the sedative type, but rather encourage the use of sedatives that are already routinely used in participating ICUs (typically a...” NCT05849779 ↗ “Induction will be done by fentanyl ( 2 mcg/kg ) , titrating dose of propofol according to patient hemodynamic response and atracurium ( 0.5 mg/kg ) to facilitate tracheal...” NCT05897151 ↗ “In the TIVA group (total intravenous anaesthesia group), induction and maintenance of anaesthesia will be performed using target-controlled infusion (TCI) with propofol...” NCT07325669 ↗ “High-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic...” NCT05263674 ↗ “Induction of anesthesia will be the same for all patients and consist of intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle...” NCT05958589 ↗ “Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation or high-flow nasal cannula oxygen therapy (if...” NCT05718024 ↗ |
| Known as | 2, 6-diisopropyl phenol | “Propofol, known chemically as 2, 6-diisopropyl phenol, is an organic compound with the chemical formula C12H18O and is a short-acting intravenous anesthetic used for the...” NCT05606315 ↗6“Propofol (2, 6 - diisopropylphenol), a highly liposoluble anaesthetic, has a potent antioxidant activity against lipid peroxidation in both in vitron and in vivo studies.” NCT01334424 ↗ “Intravenous anesthetic, propofol (2,6-diisopropylphenol), is extensively used for general anesthesia without knowing the effects on cancer.” PMID 12127688 ↗ Oct 2002 “Propofol (2,6-diisopropylphenol) is one of the most common induction and sedative agents used today.” NCT01401049 ↗ “Active agent: Propofolum (2,6-Diisopropylphenol). Route of administration: intravenous” NCT03844841 ↗ “Propofol (2,6-diisopropylphenol) is an intravenous anesthetic.” NCT06423846 ↗ “Propofol (2,6-diisopropylphenol) is a hypnotic agent” NCT05466279 ↗ |
| Known as | ANESVAN INJECTION 10MG/ML (PROPOFOL) "CHI SHENG" | “ANESVAN INJECTION 10MG/ML (PROPOFOL) "CHI SHENG"” NCT05606692 ↗ |
| Known as | Diprivan | “Diprivan/Propofol is a short-acting intravenous anesthetic used in PROSOMNIA Sleep Therapy to induce rapid and controlled REM sleep.” NCT06644573 ↗11“The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).” NCT02659228 ↗ “Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.” NCT01006668 ↗ “0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).” NCT02079090 ↗ “Drug: Propofol Injection [Diprivan]” NCT04291794 ↗ “Diprivan (propofol, Astra Zeneca)” NCT00541918 ↗ “Propofol Injection [Diprivan]” NCT04213833 ↗ “Propofol, Diprivan, Fresenius” NCT01279499 ↗ “ICI35,868 (Diprivan)” NCT01961349 ↗ |
| Known as | Diprivan 2% | “The drug in evaluation is Propofol 2% (Diprivan 2%, Astra Zeneca UK) administered as a target controlled infusion using the commercially available paediatric TCI models...” NCT01932424 ↗ |
| Known as | Diprivan-Astra Zeneca | “Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.” NCT00757458 ↗ |
| Known as | Diprivant | “Control group: will receive sedation with Propofol (Diprivant) at doses of 20-50mcg/kg/min and fentanyl (Fentanest) at doses of 1 to 2mcg/kg /hour.” NCT04998253 ↗ |
| Known as | Fresofol | “adjust propofol (FRESOFOL MCT INJ 2% (vial), Fresinus Kabi Korea) concentration maintaining the 40 \~ 50 BIS” NCT02609087 ↗ |
| Known as | Fresofol (2% propofol, Fresinius Kabi) | “Fresofol (2% propofol, Fresinius Kabi)” NCT01826149 ↗ |
| Known as | ICI35,868 | “ICI35,868 (propofol)” NCT01189604 ↗ |
| Known as | Lipid emulsion propofol: Diprivan | “Lipid emulsion propofol: Diprivan®” NCT00908726 ↗ |
| Known as | Microemulsion propofol: AquafolTM | “Microemulsion propofol: AquafolTM” NCT00908726 ↗ |
| Known as | N01AX03 - Propofol | “N01AX03 - Propofol” NCT02651792 ↗ |
| Known as | Pofol | “In Group PR, a bolus injection of 1 mg/kg of propofol was followed by a continuous infusion at a rate of 3-5mg/hr/kg(Pofol®, Dongkook Pharm. Co. Ltd., Seoul, Korea) using an...” NCT01920113 ↗ |
| Known as | Pro | “Microdialysis probes were implanted in three groups of 10 patients each receiving either sevoflurane (SEVO), propofol (PRO), or spinal (SA) anaesthesia (for induction and maintenance).” PMID 18029344 ↗ Nov 20072“Alfentanil (Alf) is used in combination with Propofol (Pro) in fiber-bronchoscopy and in many other conscious sedation procedures.” NCT01470170 ↗ “Drug: Propofol (PRO)” NCT07556133 ↗ |
| Known as | Propofol (Diprivan) | “Propofol (Diprivan)” NCT07211828 ↗1“Propofol (Diprivan)” NCT07267377 ↗ |
| Known as | propofol (Fresofol(R)2 MCT 2%, Fresenius Kabi) | “propofol (Fresofol(R)2 MCT 2%, Fresenius Kabi)” NCT02191371 ↗ |
| Known as | Propofol 1 % Injectable Suspension | “Drug: Propofol 1 % Injectable Suspension” NCT02953210 ↗ |
| Known as | Propofol 2% (20 mg/mL) MCT Fresenius | “Propofol 2% (20 mg/mL) MCT Fresenius” NCT01856998 ↗ |
| Known as | Propofol = Propofolum = Diprivan = Disoprivan | “Propofol = Propofolum = Diprivan = Disoprivan” NCT01567657 ↗ |
| Known as | Propofol Fresenius | “Drug: Propofol Fresenius” NCT04664595 ↗1“Drug: Propofol Fresenius” NCT04872881 ↗ |
| Known as | Propofol Injectable Emulsion | “A Randomized, Open-Label, Single-Bolus, 2-Period, Multi-Dose Level, 3 Cohort Crossover Design, Pharmacokinetic/Pharmacodynamic Study of Lusedra (Fospropofol Disodium) Injection...” NCT01260142 ↗ |
| Known as | Propofol injection | “Drug: Propofol injection” NCT06867068 ↗ |
| Known as | Propofol Injection 1% | “Propofol Injection 1%” NCT04164264 ↗ |
| Known as | Propofol Kabi | “Propofol (Propofol Kabi, Registration number from the State Register of Medicines - 000875) is a widely used intravenous anesthetic.” NCT04695509 ↗1“Propofol (1 group (Propofol Kabi, Registration number from the State Register of Medicines - 000875))” NCT05045170 ↗ |
| Known as | Propofol Lipuro | “Propofol Lipuro (Propofol, B-Braun) Fentanyl (Fentanyl, J&J)” NCT02732132 ↗ |
| Known as | Propofol Medium and Long Chain Fat Emulsion Injection | “IV Propofol Medium and Long Chain Fat Emulsion Injection” NCT06222294 ↗ |
| Known as | Propofolum | “Active agent: Propofolum (2,6-Diisopropylphenol). Route of administration: intravenous” NCT03844841 ↗ |
| Known as | Propoven | “Anaesthesia induction in Group P was performed with propofol (Propoven, Fresenius Kabi) and in Group S with sevoflurane (Sevorane, Abbott Laboratories).” NCT02229201 ↗ |
| Known as | total intravenous anesthesia | “total intravenous anesthesia” NCT05926336 ↗ |
| Action | Activate | “Propofol is known to stimulate gamma - aminobutyric acid- A (GABA-A) receptors by enhancing channel opening” NCT00228267 ↗ |
| Modality | Small molecule | “Propofol (2,6 di-isopropylphenol) is available as an emulsion of 1 % propofol in 10% soyabean oil, 2% glycerol and 1.2% egg phosphatide.” NCT00228267 ↗ |
| Route | Intravenous | “IV propofol sedation” NCT00192959 ↗ |
| Target | NOS2 | “propofol inhibits superoxide formation or downregulates iNOS gene expression in cardiac tissue.” NCT00734383 ↗ |